<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02721238</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-Cirrhosis-03</org_study_id>
    <nct_id>NCT02721238</nct_id>
  </id_info>
  <brief_title>Comparison of Colloid (20% Albumin) Versus Crystalloid (Plasmalyte) for Fluid Resuscitation in Cirrhotics With Sepsis Induced Hypotension.</brief_title>
  <official_title>Comparison of Colloid (20% Albumin) Versus Crystalloid (Plasmalyte) for Fluid Resuscitation in Cirrhotics With Sepsis Induced Hypotension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Consecutive cirrhotics who present to emergency department of Institute of Liver &amp; Biliary&#xD;
      Sciences with documented or suspected sepsis induced hypotension will be randomized to&#xD;
      receive either human albumin infusion over 3 hours or plasmalyte as per requirement. At&#xD;
      admission, all patients will undergo physical examination and baseline investigations to&#xD;
      identify site of sepsis. The aim of study is to compare the efficacy of using 20% human&#xD;
      albumin versus plasmalyte in resuscitation of the patient that is attainment of mean arterial&#xD;
      pressure above 65 mm of Hg at three hour after intervention and sustenance of mean arterial&#xD;
      pressure above 65 mm of Hg at 6th hour. The randomized patient will be administered 20%&#xD;
      albumin (0.5-1.0 gm/kg) for 3 hours, or plasmalyte at the rate of 30ml/kg. After the&#xD;
      intervention changes in MAP (Mean Arterial Pressure), lactate level, urine output, incidence&#xD;
      of complications, duration of ventilator, ICU (Intensive Care Unit) stay and mortality after&#xD;
      one week will be studied.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Actual">November 3, 2018</completion_date>
  <primary_completion_date type="Actual">November 3, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reversal of hypotension in both groups</measure>
    <time_frame>3 hours</time_frame>
    <description>Reversal is defined as Mean Arterial Pressure (MAP) &gt; 65 mmHg after 3 hours of resuscitation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality in both groups</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival time during the first 28 days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with new organ failures.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement of renal-replacement therapy.</measure>
    <time_frame>28 days</time_frame>
    <description>Renal-replacement therapy. is defined as patients who required hemodialysis , SLED (Sustained Low efficiency Dialysis) or CRRT (Continous renal replacement therapy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of the Intensive Care Unit stay.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Cirrhosis With Sepsis</condition>
  <arm_group>
    <arm_group_label>Resuscitation with 30ml/kg plasmalyte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Resuscitation with 20% Albumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>20% Albumin</intervention_name>
    <arm_group_label>Resuscitation with 20% Albumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Plasmalyte</intervention_name>
    <arm_group_label>Resuscitation with 30ml/kg plasmalyte</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of cirrhosis with suspected or documented sepsis with MAP &lt; 65 mm Hg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years or &gt; 75 yrs&#xD;
&#xD;
          -  Already received colloid or 2 litres of fluid within the first 12 hours of&#xD;
             presentation&#xD;
&#xD;
          -  Already on vasopressors and/or inotropes&#xD;
&#xD;
          -  Patients with Spontaneous Bacterial Peritonitis and serum albumin less then 1.5g/dl&#xD;
&#xD;
          -  Patient with structural heart disease&#xD;
&#xD;
          -  On maintenance hemodialysis&#xD;
&#xD;
          -  Other causes of hypotension&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patients in need for emergent surgical interventions&#xD;
&#xD;
          -  Known chronic obstructive lung disease and congestive heart failure&#xD;
&#xD;
          -  A previous adverse reaction to human albumin solution&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Abhinav Verma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver and Biliary Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <last_update_submitted>August 21, 2021</last_update_submitted>
  <last_update_submitted_qc>August 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma-lyte 148</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

